PortfoliosLab logoPortfoliosLab logo
NGD.TO vs. CPRX
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

NGD.TO vs. CPRX - Performance Comparison

The chart below illustrates the hypothetical performance of a CA$10,000 investment in New Gold Inc. (NGD.TO) and Catalyst Pharmaceuticals, Inc. (CPRX). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

NGD.TO vs. CPRX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NGD.TO
New Gold Inc.
1.67%233.15%86.98%44.36%-29.63%-32.50%143.48%9.52%-74.58%-12.31%
CPRX
Catalyst Pharmaceuticals, Inc.
7.52%6.71%34.82%-11.61%194.32%100.86%-12.44%85.71%-46.73%248.67%
Different Trading Currencies

NGD.TO is traded in CAD, while CPRX is traded in USD. To make them comparable, the CPRX values have been converted to CAD using the latest available exchange rates.

Fundamentals

Market Cap

NGD.TO:

CA$9.63B

CPRX:

$3.15B

EPS

NGD.TO:

CA$1.09

CPRX:

$1.68

PE Ratio

NGD.TO:

11.16

CPRX:

14.71

PEG Ratio

NGD.TO:

0.02

CPRX:

0.26

PS Ratio

NGD.TO:

6.49

CPRX:

5.35

PB Ratio

NGD.TO:

5.04

CPRX:

3.30

Total Revenue (TTM)

NGD.TO:

CA$1.49B

CPRX:

$588.99M

Gross Profit (TTM)

NGD.TO:

CA$767.09M

CPRX:

$726.82M

EBITDA (TTM)

NGD.TO:

CA$810.05M

CPRX:

$257.78M

Returns By Period

In the year-to-date period, NGD.TO achieves a 1.67% return, which is significantly lower than CPRX's 7.52% return. Over the past 10 years, NGD.TO has underperformed CPRX with an annualized return of 10.00%, while CPRX has yielded a comparatively higher 36.25% annualized return.


NGD.TO

1D
0.00%
1M
-33.62%
YTD
1.67%
6M
21.97%
1Y
128.57%
3Y*
106.05%
5Y*
42.91%
10Y*
10.00%

CPRX

1D
4.01%
1M
9.40%
YTD
7.52%
6M
25.57%
1Y
-1.30%
3Y*
15.40%
5Y*
43.51%
10Y*
36.25%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NGD.TO vs. CPRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NGD.TO
NGD.TO Risk / Return Rank: 9393
Overall Rank
NGD.TO Sharpe Ratio Rank: 9595
Sharpe Ratio Rank
NGD.TO Sortino Ratio Rank: 9090
Sortino Ratio Rank
NGD.TO Omega Ratio Rank: 9191
Omega Ratio Rank
NGD.TO Calmar Ratio Rank: 9393
Calmar Ratio Rank
NGD.TO Martin Ratio Rank: 9696
Martin Ratio Rank

CPRX
CPRX Risk / Return Rank: 4141
Overall Rank
CPRX Sharpe Ratio Rank: 4444
Sharpe Ratio Rank
CPRX Sortino Ratio Rank: 3838
Sortino Ratio Rank
CPRX Omega Ratio Rank: 3737
Omega Ratio Rank
CPRX Calmar Ratio Rank: 4242
Calmar Ratio Rank
CPRX Martin Ratio Rank: 4141
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NGD.TO vs. CPRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for New Gold Inc. (NGD.TO) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NGD.TOCPRXDifference

Sharpe ratio

Return per unit of total volatility

2.60

-0.04

+2.64

Sortino ratio

Return per unit of downside risk

2.81

0.19

+2.63

Omega ratio

Gain probability vs. loss probability

1.41

1.02

+0.38

Calmar ratio

Return relative to maximum drawdown

4.56

-0.10

+4.66

Martin ratio

Return relative to average drawdown

17.34

-0.18

+17.51

NGD.TO vs. CPRX - Sharpe Ratio Comparison

The current NGD.TO Sharpe Ratio is 2.60, which is higher than the CPRX Sharpe Ratio of -0.04. The chart below compares the historical Sharpe Ratios of NGD.TO and CPRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


NGD.TOCPRXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.60

-0.04

+2.64

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.71

0.93

-0.22

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.16

0.59

-0.43

Sharpe Ratio (All Time)

Calculated using the full available price history

0.01

0.17

-0.16

Correlation

The correlation between NGD.TO and CPRX is 0.03, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

NGD.TO vs. CPRX - Dividend Comparison

Neither NGD.TO nor CPRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NGD.TO vs. CPRX - Drawdown Comparison

The maximum NGD.TO drawdown since its inception was -98.39%, which is greater than CPRX's maximum drawdown of -90.42%. Use the drawdown chart below to compare losses from any high point for NGD.TO and CPRX.


Loading graphics...

Drawdown Indicators


NGD.TOCPRXDifference

Max Drawdown

Largest peak-to-trough decline

-98.39%

-94.25%

-4.14%

Max Drawdown (1Y)

Largest decline over 1 year

-35.75%

-27.29%

-8.46%

Max Drawdown (5Y)

Largest decline over 5 years

-69.29%

-45.37%

-23.92%

Max Drawdown (10Y)

Largest decline over 10 years

-91.12%

-64.87%

-26.25%

Current Drawdown

Current decline from peak

-71.56%

-5.89%

-65.67%

Average Drawdown

Average peak-to-trough decline

-80.86%

-52.51%

-28.35%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.41%

15.10%

-5.69%

Volatility

NGD.TO vs. CPRX - Volatility Comparison

New Gold Inc. (NGD.TO) has a higher volatility of 20.35% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 10.16%. This indicates that NGD.TO's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


NGD.TOCPRXDifference

Volatility (1M)

Calculated over the trailing 1-month period

20.35%

10.16%

+10.19%

Volatility (6M)

Calculated over the trailing 6-month period

50.26%

23.52%

+26.74%

Volatility (1Y)

Calculated over the trailing 1-year period

62.83%

34.65%

+28.18%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

60.65%

46.88%

+13.77%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

63.57%

61.94%

+1.63%

Financials

NGD.TO vs. CPRX - Financials Comparison

This section allows you to compare key financial metrics between New Gold Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
523.32M
152.61M
(NGD.TO) Total Revenue
(CPRX) Total Revenue
Please note, different currencies. NGD.TO values in CAD, CPRX values in USD